A Multi-center Open-label Long-term Extension Study of ABI-H0731 + Nucleos(t)ide as Finite Treatment for Chronic Hepatitis B Patients

Brief description of study

The purpose of this extension study is to determine the long-term safety and antiviral effects of ABI H0731 when taken with a standard of care medication for men and women with chronic HBV infection. The purpose of this extension study is to determine the long-term safety and antiviral effects of ABI H0731 when taken with a standard of care medication for men and women with chronic HBV infection. ABI H0731 (the study drug) is an experimental drug being developed by the Sponsor of this study. ABI- H0731 has been given to subjects with and without HBV infection and was found to be well-tolerated, with few and manageable side effects. This study is designed to see if ABI-H0731 has the potential to improve the treatment of chronic HBV infection. Combination therapy with ABI-H0731 together with standard of care medicines is being studied to see if the combination can lower the amount of HBV in the liver even more than the standard of care HBV medications alone. To understand the potential risks and benefits, this study will look at up to 12 months of combination therapy of ABI-H0731 together with the standard HBV medicine that is already taken to see if it might offer longer lasting and better responses in CHB patients than in patients taking standard HBV medications alone.


Clinical Study Identifier: s18-01960
ClinicalTrials.gov Identifier: NCT03780543
Principal Investigator: Ira M. Jacobson
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.